Another effect of statins: it can reduce the intestinal flora imbalance of obese people!

There are a large number of microorganisms in the human body. They help humans digest and absorb nutrients, synthesize vitamins, participate in the regulation of metabolism and immune function, and even affect emotions and cognitive behaviors. Of course, they can also cause people to get sick . It is conservatively estimated that the ratio of the number of microorganisms to cells in the human body is about 1. 3:1. In the intestine, the number of bacterial genes is more than 100 times that of the human host genes . Therefore, the normal intestinal flora has a potential impact on human health that cannot be ignored . Studies have pointed out that obesity and obesity-related comorbidities are related to changes in the fecal microbiome, that is, intestinal flora, including a decrease in the abundance of the fecal community and a decrease in the abundance of butyrate-producing bacteria . On this basis, researchers from the University of Leuven, Belgium, combined metagenomics, metabolomics and clinical methods to carry out a large-scale observational cohort study on gut microbes . The results found that Bact2 intestinal type is a potential dysbacterial intestinal type related to systemic inflammation, which is more common in obese people, and taking statins (classic drugs for lowering cholesterol, the treatment and prevention of cardiovascular and cerebrovascular diseases) can reduce the intestine The incidence of tract dysbacteriosis . Related research results were published in the journal Nature on May 6, local time . doi. org/10. 1038/s41586-020-2269-x 　　Previously, the research team divided the human intestinal microbiota into four types of "intestinal types" based on the types of bacteria that have a dominant position in the intestine: Bacteroides type 1 (Bact1 ), Bacteroides type 2 (Bact2), rumen cocci type (Rum) and Prevotella type (Prev) . 　　In this study, the researchers recruited more than 2,000 healthy and cardiometabolic disease participants, including 888 BMIS cohort members (median BMI = 31. 5 kg/m-2), and metagenomics of their stool samples Sequencing and annotation . Since more than 42% of the participants are taking more than one drug, the analysis of whether to take drugs and their types combined with metagenomic data found that statins are a key covariate for the diversification of the gut microbiome . 　　In further analysis of the participants who did not take statins, it was found that the Bact2 intestinal type was more common in obese patients. The incidence of Bact2 in the thinner population was 3. 9%, while the incidence of this intestinal type in obese patients It is 17. 7% . In addition, the level of inflammation in individuals with Bact2 intestinal type is also higher than predicted based on BMI alone, which indicates that Bact2 is a poor intestinal flora structure related to systemic inflammation . Changes of the microbiome in the BMIS population not taking statins Changes in intestinal characteristics and prevalence of non-statin-treated BMIS population . 　　Through the analysis and comparison of people taking statins, it was found that the incidence of Bact2 intestinal type was negatively correlated with the use of statins. Among obese patients taking statins, the incidence of Bact2 dropped from 17. 73%. 5. 88% . This conclusion was further confirmed in the MetaCardis cardiovascular disease data set (n=282) and the independent Flemish intestinal flora project population (n=2345) analysis . The prevalence of Bact2 intestinal type, the association between obesity and statin intake 　　In short, researchers have found that the incidence of bad intestinal type Bact2 is higher in obese people, but taking statins can reduce its incidence . However, the researchers also pointed out in the report that the potential benefits of statins need to be further evaluated in prospective clinical trials to determine whether this effect can be reproduced in a randomized population and whether it can be considered for intestinal use. Tract flora regulating therapeutic agent . [1] Statin therapy is associated with lower prevalence of gut microbiota dysbiosis [2] The neuroactive potential of the human gut microbiota in quality of life and depression. This article is a biological exploration and original, and personal sharing is welcome . If any other media or website needs to be reprinted, the source must be indicated before the main text .   Disclaimer: This article only represents the author's personal views and has nothing to do with China Probiotics. com . The originality and the text and content stated in the article have not been verified by this site. This site does not make any guarantee or commitment to the authenticity, completeness, and timeliness of this article, all or part of the content, and the text. Please readers for reference only, and please Verify the relevant content yourself .   Copyright Notice 1. Some of the reprinted articles on this site are not original, and the copyright and liability belong to the original author . 2. All reprinted articles, links and pictures on this website are for the purpose of conveying more information, and clearly indicate the source and author. Media or individuals who do not want to be reprinted can contact us for infringement information that can provide sufficient evidence , Bio149 will be deleted within 12 hours after confirmation . 3. Users are welcome to post original articles to 86371366@qq. com, and post to the homepage after review. The copyright and responsibility for the original article belong to the sender .

　　There are a large number of microorganisms in the human body.
They help humans digest and absorb nutrients, synthesize vitamins, participate in the regulation of metabolism and immune function, and even affect emotions and cognitive behaviors.
Of course, they can also cause people to get sick
.
It is conservatively estimated that the ratio of the number of microorganisms to cells in the human body is about 1.
3:1.
In the intestine, the number of bacterial genes is more than 100 times that of the human host genes
.
Therefore, the normal intestinal flora has a potential impact on human health that cannot be ignored
.


　　Studies have pointed out that obesity and obesity-related comorbidities are related to changes in the fecal microbiome, that is, intestinal flora, including a decrease in the abundance of the fecal community and a decrease in the abundance of butyrate-producing bacteria
.
On this basis, researchers from the University of Leuven, Belgium, combined metagenomics, metabolomics and clinical methods to carry out a large-scale observational cohort study on gut microbes
.
The results found that Bact2 intestinal type is a potential dysbacterial intestinal type related to systemic inflammation, which is more common in obese people, and taking statins (classic drugs for lowering cholesterol, the treatment and prevention of cardiovascular and cerebrovascular diseases) can reduce the intestine The incidence of tract dysbacteriosis
.
Related research results were published in the journal Nature on May 6, local time
.

doi.
org/10.
1038/s41586-020-2269-x

　　Previously, the research team divided the human intestinal microbiota into four types of "intestinal types" based on the types of bacteria that have a dominant position in the intestine: Bacteroides type 1 (Bact1 ), Bacteroides type 2 (Bact2), rumen cocci type (Rum) and Prevotella type (Prev)
.


　　In this study, the researchers recruited more than 2,000 healthy and cardiometabolic disease participants, including 888 BMIS cohort members (median BMI = 31.
5 kg/m-2), and metagenomics of their stool samples Sequencing and annotation
.
Since more than 42% of the participants are taking more than one drug, the analysis of whether to take drugs and their types combined with metagenomic data found that statins are a key covariate for the diversification of the gut microbiome
.


　　In further analysis of the participants who did not take statins, it was found that the Bact2 intestinal type was more common in obese patients.
The incidence of Bact2 in the thinner population was 3.
9%, while the incidence of this intestinal type in obese patients It is 17.
7%
.
In addition, the level of inflammation in individuals with Bact2 intestinal type is also higher than predicted based on BMI alone, which indicates that Bact2 is a poor intestinal flora structure related to systemic inflammation
.


Changes of the microbiome in the BMIS population not taking statins

Changes in intestinal characteristics and prevalence of non-statin-treated BMIS population
.


　　Through the analysis and comparison of people taking statins, it was found that the incidence of Bact2 intestinal type was negatively correlated with the use of statins.
Among obese patients taking statins, the incidence of Bact2 dropped from 17.
73%.
5.
88%
.
This conclusion was further confirmed in the MetaCardis cardiovascular disease data set (n=282) and the independent Flemish intestinal flora project population (n=2345) analysis
.


The prevalence of Bact2 intestinal type, the association between obesity and statin intake

　　In short, researchers have found that the incidence of bad intestinal type Bact2 is higher in obese people, but taking statins can reduce its incidence
.
However, the researchers also pointed out in the report that the potential benefits of statins need to be further evaluated in prospective clinical trials to determine whether this effect can be reproduced in a randomized population and whether it can be considered for intestinal use.
Tract flora regulating therapeutic agent
.


[1] Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

[2] The neuroactive potential of the human gut microbiota in quality of life and depression.


This article is a biological exploration and original, and personal sharing is welcome
.
If any other media or website needs to be reprinted, the source must be indicated before the main text
.

---

　　There are a large number of microorganisms in the human body.
They help humans digest and absorb nutrients, synthesize vitamins, participate in the regulation of metabolism and immune function, and even affect emotions and cognitive behaviors.
Of course, they can also cause people to get sick
.
It is conservatively estimated that the ratio of the number of microorganisms to cells in the human body is about 1.
3:1.
In the intestine, the number of bacterial genes is more than 100 times that of the human host genes
.
Therefore, the normal intestinal flora has a potential impact on human health that cannot be ignored
.


　　Studies have pointed out that obesity and obesity-related comorbidities are related to changes in the fecal microbiome, that is, intestinal flora, including a decrease in the abundance of the fecal community and a decrease in the abundance of butyrate-producing bacteria
.
On this basis, researchers from the University of Leuven, Belgium, combined metagenomics, metabolomics and clinical methods to carry out a large-scale observational cohort study on gut microbes
.
The results found that Bact2 intestinal type is a potential dysbacterial intestinal type related to systemic inflammation, which is more common in obese people, and taking statins (classic drugs for lowering cholesterol, the treatment and prevention of cardiovascular and cerebrovascular diseases) can reduce the intestine The incidence of tract dysbacteriosis
.
Related research results were published in the journal Nature on May 6, local time
.

doi.
org/10.
1038/s41586-020-2269-x

　　Previously, the research team divided the human intestinal microbiota into four types of "intestinal types" based on the types of bacteria that have a dominant position in the intestine: Bacteroides type 1 (Bact1 ), Bacteroides type 2 (Bact2), rumen cocci type (Rum) and Prevotella type (Prev)
.


　　In this study, the researchers recruited more than 2,000 healthy and cardiometabolic disease participants, including 888 BMIS cohort members (median BMI = 31.
5 kg/m-2), and metagenomics of their stool samples Sequencing and annotation
.
Since more than 42% of the participants are taking more than one drug, the analysis of whether to take drugs and their types combined with metagenomic data found that statins are a key covariate for the diversification of the gut microbiome
.


　　In further analysis of the participants who did not take statins, it was found that the Bact2 intestinal type was more common in obese patients.
The incidence of Bact2 in the thinner population was 3.
9%, while the incidence of this intestinal type in obese patients It is 17.
7%
.
In addition, the level of inflammation in individuals with Bact2 intestinal type is also higher than predicted based on BMI alone, which indicates that Bact2 is a poor intestinal flora structure related to systemic inflammation
.


Changes of the microbiome in the BMIS population not taking statins

Changes in intestinal characteristics and prevalence of non-statin-treated BMIS population
.


　　Through the analysis and comparison of people taking statins, it was found that the incidence of Bact2 intestinal type was negatively correlated with the use of statins.
Among obese patients taking statins, the incidence of Bact2 dropped from 17.
73%.
5.
88%
.
This conclusion was further confirmed in the MetaCardis cardiovascular disease data set (n=282) and the independent Flemish intestinal flora project population (n=2345) analysis
.


Bact2，

　　，Bact2，
。，，，
。

[1] Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

[2] The neuroactive potential of the human gut microbiota in quality of life and depression.


，
。、，
。

---

　　There are a large number of microorganisms in the human body.
They help humans digest and absorb nutrients, synthesize vitamins, participate in the regulation of metabolism and immune function, and even affect emotions and cognitive behaviors.
Of course, they can also cause people to get sick
.
It is conservatively estimated that the ratio of the number of microorganisms to cells in the human body is about 1.
3:1.
In the intestine, the number of bacterial genes is more than 100 times that of the human host genes
.
Therefore, the normal intestinal flora has a potential impact on human health that cannot be ignored
.


　　Studies have pointed out that obesity and obesity-related comorbidities are related to changes in the fecal microbiome, that is, intestinal flora, including a decrease in the abundance of the fecal community and a decrease in the abundance of butyrate-producing bacteria
.
On this basis, researchers from the University of Leuven, Belgium, combined metagenomics, metabolomics and clinical methods to carry out a large-scale observational cohort study on gut microbes
.
The results found that Bact2 intestinal type is a potential dysbacterial intestinal type related to systemic inflammation, which is more common in obese people, and taking statins (classic drugs for lowering cholesterol, the treatment and prevention of cardiovascular and cerebrovascular diseases) can reduce the intestine The incidence of tract dysbacteriosis
.
Related research results were published in the journal Nature on May 6, local time
.

doi.
org/10.
1038/s41586-020-2269-x

　　Previously, the research team divided the human intestinal microbiota into four types of "intestinal types" based on the types of bacteria that have a dominant position in the intestine: Bacteroides type 1 (Bact1 ), Bacteroides type 2 (Bact2), rumen cocci type (Rum) and Prevotella type (Prev)
.


　　In this study, the researchers recruited more than 2,000 healthy and cardiometabolic disease participants, including 888 BMIS cohort members (median BMI = 31.
5 kg/m-2), and metagenomics of their stool samples Sequencing and annotation
.
Since more than 42% of the participants are taking more than one drug, the analysis of whether to take drugs and their types combined with metagenomic data found that statins are a key covariate for the diversification of the gut microbiome
.


　　In further analysis of the participants who did not take statins, it was found that the Bact2 intestinal type was more common in obese patients.
The incidence of Bact2 in the thinner population was 3.
9%, while the incidence of this intestinal type in obese patients It is 17.
7%
.
In addition, the level of inflammation in individuals with Bact2 intestinal type is also higher than predicted based on BMI alone, which indicates that Bact2 is a poor intestinal flora structure related to systemic inflammation
.


Changes of the microbiome in the BMIS population not taking statinsChanges in intestinal characteristics and prevalence of non-statin-treated BMIS population
.


　　Through the analysis and comparison of people taking statins, it was found that the incidence of Bact2 intestinal type was negatively correlated with the use of statins.
Among obese patients taking statins, the incidence of Bact2 dropped from 17.
73%.
5.
88%
.
This conclusion was further confirmed in the MetaCardis cardiovascular disease data set (n=282) and the independent Flemish intestinal flora project population (n=2345) analysis
.


The prevalence of Bact2 intestinal type, the association between obesity and statin intake

　　In short, researchers have found that the incidence of bad intestinal type Bact2 is higher in obese people, but taking statins can reduce its incidence
.
However, the researchers also pointed out in the report that the potential benefits of statins need to be further evaluated in prospective clinical trials to determine whether this effect can be reproduced in a randomized population and whether it can be considered for intestinal use.
Tract flora regulating therapeutic agent
.


[1] Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

[2] The neuroactive potential of the human gut microbiota in quality of life and depression.


This article is a biological exploration and original, and personal sharing is welcome
.
If any other media or website needs to be reprinted, the source must be indicated before the main text
.

---